Answers are grounded in this paper and cite their sources.
Reviews diagnostics and emerging strategies to manage AAV pre-existing immunity, highlighting implications for gene therapies.
“Should IdeS treatment become standard, the use of assays to detect pre-existing antibodies may shift toward verifying IgG cleavage to confirm an adequate dosing window.”Pre-existing immunity to AAV limits the safety and efficacy of intravenous gene therapies, necessitating robust companion diagnostics for patient selection. This paper reviews current NAb and TAb assay approaches, standardization efforts, and emerging strategies, including engineered capsids and IgG-cleaving enzymes, that aim to overcome immunity and inform future diagnostic development.
No takes yet. Share an insight, caveat, or question.
Katherine Block (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: